Lupin's approved tablets, indicated for the treatment of HIV-1 infection, are bioequivalent to Merck Sharp & Dohme LLC’s ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product ...

On April 2, 2025, Cingulate completed its Pre-NDA meeting with the FDA to discuss the submission of an NDA for CTx-1301, its ...

IASO Biotherapeutics ('IASO Bio'), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

CDSCO revises guidelines for issuance of export NOC for unapproved, approved new drugs: Gireesh Babu, New Delhi Friday, May 9, 2025, 08:00 Hrs [IST] The Central Drugs Standard Con ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.